Table 2.
Proportions of NY-ESO-specific T cell responders determined by ICS in Stage I
| Treatment | Response | n | % | 95% CI for proportion | P-valueb |
|---|---|---|---|---|---|
|
DCV (n = 17) |
All (CD4+ and/or CD8+) |
14 | 82.35 | (56.57 to 96.20) | 1.0 |
|
DCV + α-GalCer (n= 15)a |
13 | 86.67 | (59.54 to 98.34) | ||
|
DCV (n = 17) |
No response | 3 | 17.65 | (3.80 to 43.43) | 0.7922 |
| CD4+ only | 9 | 52.94 | (40.42 to 80.84) | ||
| CD8+ only | 0 | 0.00 | NA | ||
| Both CD4+ and CD8+ | 5 | 29.41 | (10.31 to 55.96) | ||
|
DCV + α-GalCer (n = 15)a |
No response | 2 | 13.33 | (1.66 to 40.46) | |
| CD4+ only | 10 | 66.67 | (38.38 to 88.18) | ||
| CD8+ only | 0 | 0.00 | NA | ||
| Both CD4+ and CD8+ | 3 | 20.00 | (4.33 to 48.069) |
aPatient 2–043 excluded due to insufficient cells
bFisher's exact test (as 50% expected counts < 5)